Analyst Price Targets — PHAR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 12:55 pm | — | Oppenheimer | $40.00 | $12.91 | TheFly | Pharming price target lowered to $40 from $41 at Oppenheimer |
| April 10, 2026 10:59 am | Whitney Ijem | Canaccord Genuity | $37.00 | $17.50 | TheFly | Pharming initiated with a Buy at Canaccord on growth potential |
| March 12, 2026 3:53 pm | Joseph Pantginis | H.C. Wainwright | $37.00 | $15.58 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value" |
| November 7, 2025 1:27 pm | — | Oppenheimer | $42.00 | $15.96 | TheFly | Pharming price target raised to $42 from $41 at Oppenheimer |
| December 9, 2024 9:36 am | Lucy Codrington | Jefferies | $14.00 | $7.72 | StreetInsider | Jefferies Starts Pharming Group (PHAR) at Buy |
Latest News for PHAR
If approved, Joenja will be the first approved treatment in the U. S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosingSeparate sNDA for lower weight pediatric patients planned for second half 2026 Leiden, the Netherlands, June 4, 2026:…
Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue…
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHAR.
U.S. House Trading
No House trades found for PHAR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.